Claim Verification: "GLP-1 drugs like Ozempic cause unavoidable major muscle loss and "Ozempic face" even with exercise and high protein intake" — Disproved

Automated fact-verification of the claim: "GLP-1 drugs like Ozempic cause unavoidable major muscle loss and "Ozempic face" even with exercise and high protein intake" Verdict: DISPROVED Key Findings SC1 (muscle loss) — DISPROVED: 3 of 3 independently verified sources confirm that resistance exercise and high protein intake substantially mitigate lean-mass loss during GLP-1 therapy. Two of three patients in the primary case series (Tinsley & Nadolsky, 2025) achieved net lean-mass gains while losing significant total body weight — the precise opposite of "unavoidable major muscle loss." SC2 ("Ozempic face") — DISPROVED: 2 of 2 independently verified sources confirm that "Ozempic face" is not a GLP-1-specific pharmacological effect. A 2025 systematic review found that "evidence to suggest that GLP-1 receptor agonists preferentially result in facial fat atrophy is lacking." The effect mirrors general rapid weight-loss-related facial volume reduction. No counter-evidence found: Adversarial searches found no published study demonstrating lean-mass loss is unavoidable despite structured exercise + high protein. The only relevant cohort finding adverse outcomes (Ren et al., 2025) explicitly studied patients without such interventions. Overall: Both sub-claims fail. The word "unavoidable" in the original claim is directly contradicted by published clinical evidence for both SC1 and SC2. Files proof.py — Re-runnable Python verification script proof.md — Structured proof report proof_audit.md — Full verification audit trail proof_narrative.md — Plain-language summary proof.json — Machine-readable structured data Generated by Proof Engine v1.3.1.